{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T20:38:22Z","timestamp":1764794302386,"version":"3.45.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.athplu.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T22:15:35Z","timestamp":1652825735000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients"],"prefix":"10.1016","volume":"49","author":[{"given":"Fangyuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pucong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengtao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xumin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaluan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.athplu.2022.05.002_bib1","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.jacc.2020.03.058","article-title":"Familial hypercholesterolemia the most common monogenic disorder in humans","volume":"75","author":"Kastelein","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2022.05.002_bib2","first-page":"1","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"22","key":"10.1016\/j.athplu.2022.05.002_bib3","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2022.05.002_bib4","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Prim"},{"issue":"32","key":"10.1016\/j.athplu.2022.05.002_bib5","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.athplu.2022.05.002_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.athplu.2022.05.002_bib7","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1210\/jc.2012-1563","article-title":"Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication","volume":"97","author":"Benn","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.athplu.2022.05.002_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11883-002-0058-7","article-title":"Statins in homozygous familial hypercholesterolemia","volume":"4","author":"Marais","year":"2002","journal-title":"Curr Atherosclerosis Rep"},{"issue":"7","key":"10.1016\/j.athplu.2022.05.002_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamacardio.2019.0886","article-title":"Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the fourier trial","volume":"4","author":"Murphy","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"16","key":"10.1016\/j.athplu.2022.05.002_bib10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2019.11.072","article-title":"Lipid-modifying agents, from statins to PCSK9 inhibitors: JACC focus seminar","volume":"75","author":"Preiss","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9965","key":"10.1016\/j.athplu.2022.05.002_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.athplu.2022.05.002_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.athplu.2022.05.002_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nri3793","article-title":"Cholesterol, inflammation and innate immunity","volume":"15","author":"Tall","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"81","key":"10.1016\/j.athplu.2022.05.002_bib14","first-page":"1","article-title":"Enhanced status of inflammation and endothelial activation in subjects with familial hypercholesterolaemia and their related unaffected family members : a case control study","volume":"16","author":"Rahman","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.athplu.2022.05.002_bib15","first-page":"1","article-title":"Hypercholesterolemia and microvascular dysfunction: interventional strategies","volume":"7","author":"Stapleton","year":"2010","journal-title":"J\u00a0Inflamm"},{"issue":"8","key":"10.1016\/j.athplu.2022.05.002_bib16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s11745-015-4046-4","article-title":"Hypercholesterolemia induced immune response and inflammation on progression of atherosclerosis in Apobtm2Sgy Ldlrtm1Her\/J mice","volume":"50","author":"Rao","year":"2015","journal-title":"Lipids"},{"issue":"2","key":"10.1016\/j.athplu.2022.05.002_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00281-017-0656-7","article-title":"Monocyte and macrophage immunometabolism in atherosclerosis","volume":"40","author":"Groh","year":"2018","journal-title":"Semin Immunopathol"},{"issue":"10","key":"10.1016\/j.athplu.2022.05.002_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nri3520","article-title":"Macrophages in atherosclerosis: a dynamic balance","volume":"13","author":"Moore","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.athplu.2022.05.002_bib19","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00017.2013","article-title":"The role of the vascular dendritic cell network in atherosclerosis","volume":"305","author":"Alberts-Grill","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"issue":"7","key":"10.1016\/j.athplu.2022.05.002_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-020-0352-5","article-title":"T\u00a0cell subsets and functions in atherosclerosis","volume":"17","author":"Saigusa","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.athplu.2022.05.002_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41569-019-0326-7","article-title":"Neutrophils as regulators of cardiovascular inflammation","volume":"17","author":"Silvestre-Roig","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"January","key":"10.1016\/j.athplu.2022.05.002_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2020.05.018","article-title":"Platelets as therapeutic targets to prevent atherosclerosis","volume":"307","author":"Nording","year":"2020","journal-title":"Atherosclerosis"},{"issue":"16","key":"10.1016\/j.athplu.2022.05.002_bib23","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.jacc.2020.02.058","article-title":"Complement C5 protein as a marker of subclinical atherosclerosis","volume":"75","author":"Mart\u00ednez-L\u00f3pez","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.athplu.2022.05.002_bib24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.athplu.2022.05.002_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.numecd.2017.10.022","article-title":"Neutrophil-to-Lymphocyte Ratio is a strong predictor of atherosclerotic carotid plaques in older adults","volume":"28","author":"Corriere","year":"2018","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.athplu.2022.05.002_bib26","first-page":"660","article-title":"Platelet\/lymphocyte ratio and risk of in-hospital mortality in patients with ST-elevated myocardial infarction","volume":"20","author":"Temiz","year":"2014","journal-title":"Med Sci Mon Int Med J Exp Clin Res"},{"issue":"10","key":"10.1016\/j.athplu.2022.05.002_bib27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1177\/0003319720943810","article-title":"Relationship between platelet to lymphocyte ratio and stable coronary artery disease: meta-analysis of observational studies","volume":"71","author":"Qiu","year":"2020","journal-title":"Angiology"},{"issue":"11","key":"10.1016\/j.athplu.2022.05.002_bib28","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.hlc.2016.02.023","article-title":"Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome","volume":"25","author":"Cetin","year":"2016","journal-title":"Heart Lung Circ"},{"issue":"5","key":"10.1016\/j.athplu.2022.05.002_bib29","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1076029615594002","article-title":"Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation","volume":"22","author":"Canpolat","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"10.1016\/j.athplu.2022.05.002_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-017-0507-4","article-title":"Monocyte\/lymphocyte ratio predicts the severity of coronary artery disease: a syntax score assessment","volume":"17","author":"Ji","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.athplu.2022.05.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/brb3.1429","article-title":"Monocyte\/lymphocyte ratio is associated with carotid stenosis in ischemic stroke : a retrospective analysis","volume":"9","author":"Zuo","year":"2019","journal-title":"Brain Behav"},{"issue":"4","key":"10.1016\/j.athplu.2022.05.002_bib32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/0003319717743315","article-title":"The link between mean platelet volume to lymphocyte ratio and complexity of coronary artery disease","volume":"69","author":"Besli","year":"2018","journal-title":"Angiology"},{"issue":"5","key":"10.1016\/j.athplu.2022.05.002_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1003115","article-title":"The association of innate and adaptive immunity, subclinical atherosclerosis, and cardiovascular disease in the Rotterdam Study: a prospective cohort study","volume":"17","author":"Fani","year":"2020","journal-title":"PLoS Med"},{"issue":"July","key":"10.1016\/j.athplu.2022.05.002_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2020.07.027","article-title":"A\u00a0link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: clinical and therapeutic implications","volume":"309","author":"Oikonomou","year":"2020","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.athplu.2022.05.002_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s12012-019-09555-4","article-title":"Platelet function in cardiovascular disease: activation of molecules and activation by molecules","volume":"20","author":"Khodadi","year":"2020","journal-title":"Cardiovasc Toxicol"},{"issue":"16","key":"10.1016\/j.athplu.2022.05.002_bib36","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1182\/blood-2016-01-631259","article-title":"Cholesterol in platelet biogenesis and activation","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.athplu.2022.05.002_bib37","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1053\/euhj.2000.2515","article-title":"Platelet activation: assessment and quantification","volume":"22","author":"Kamath","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2022.05.002_bib38","article-title":"Challenges in reducing atherosclerotic inflammation in patients with familial hypercholesterolemia","author":"Montecucco","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.athplu.2022.05.002_bib39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00592-021-01703-z","article-title":"Effect of PCSK9 inhibitors on pulse wave velocity and monocyte - to - HDL - cholesterol ratio in familial hypercholesterolemia subjects : results from a single - lipid - unit real - life setting","volume":"58","author":"Scicali","year":"2021","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.athplu.2022.05.002_bib40","first-page":"1","article-title":"Achilles tendon ultrasonography in familial hypercholesterolemia: a sub-study of the LIpid transPort disorders Italian GEnetic Network (LIPIGEN)","author":"Baragetti","year":"2021","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"10.1016\/j.athplu.2022.05.002_bib41","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jacl.2018.10.013","article-title":"Diagnostic accuracy of ultrasound and MRI for Achilles tendon xanthoma in people with familial hypercholesterolemia: a systematic review","volume":"13","author":"Scott","year":"2019","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.athplu.2022.05.002_bib42","article-title":"Statin therapy may not effect NLR and MPV levels in patients with hypercholesterolemia: A Retrospective Study","author":"Gungoren","year":"2015","journal-title":"Angiology"},{"key":"10.1016\/j.athplu.2022.05.002_bib43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11883-011-0215-y","article-title":"Treatment of familial hypercholesterolemia: is there a need beyond Statin therapy?","volume":"14","author":"Raper","year":"2012","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.athplu.2022.05.002_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.atherosclerosissup.2019.08.029","article-title":"Efficiency and problems of statin therapy in patients with heterozygous familial hypercholesterolemia","volume":"40","author":"Korneva","year":"2019","journal-title":"Atherosclerosis Suppl"},{"issue":"1","key":"10.1016\/j.athplu.2022.05.002_bib45","first-page":"1","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.athplu.2022.05.002_bib46","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cvr\/cvz313","article-title":"PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1","volume":"116","author":"Ding","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.athplu.2022.05.002_bib47","first-page":"52","article-title":"Local effects of human PCSK9 on the atherosclerotic lesion","volume":"238","author":"Giunzioni","year":"2016","journal-title":"Physiol Behav"},{"issue":"2","key":"10.1016\/j.athplu.2022.05.002_bib48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/joim.12758","article-title":"PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque","volume":"284","author":"Liu","year":"2018","journal-title":"J\u00a0Intern Med"},{"issue":"2","key":"10.1016\/j.athplu.2022.05.002_bib49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.atherosclerosis.2014.04.001","article-title":"Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease","volume":"234","author":"Li","year":"2014","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.athplu.2022.05.002_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-14043-y","article-title":"Neutrophil microvesicles drive atherosclerosis by delivering miR-155 to atheroprone endothelium","volume":"11","author":"Gomez","year":"2020","journal-title":"Nat Commun"},{"issue":"6245","key":"10.1016\/j.athplu.2022.05.002_bib51","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.aaa8064","article-title":"Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis","volume":"349","author":"Warnatsch","year":"2015","journal-title":"Science"},{"issue":"August","key":"10.1016\/j.athplu.2022.05.002_bib52","first-page":"1","article-title":"Reactive oxygen species (ROS), intimal thickening, and subclinical atherosclerotic disease","volume":"6","author":"Burtenshaw","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.athplu.2022.05.002_bib53","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/ATVBAHA.119.312725","article-title":"Inhibition of MPO (myeloperoxidase) attenuates endothelial dysfunction in mouse models of vascular inflammation and atherosclerosis","volume":"39","author":"Cheng","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.athplu.2022.05.002_bib54","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"Bernelot Moens","year":"2017","journal-title":"Eur Heart J"},{"issue":"42","key":"10.1016\/j.athplu.2022.05.002_bib55","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1093\/eurheartj\/ehab465","article-title":"Impact of cholesterol on proinflammatory monocyte production by the bone marrow","volume":"42","author":"Stiekema","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2022.05.002_bib56","first-page":"373","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"issue":"July","key":"10.1016\/j.athplu.2022.05.002_bib57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijcard.2021.10.138","article-title":"Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the START-ANTIPLATELET registry","volume":"345","author":"Cesaro","year":"2021","journal-title":"Int J Cardiol"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089522000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089522000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:43:28Z","timestamp":1763023408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089522000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":57,"alternative-id":["S2667089522000141"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2022.05.002","relation":{},"ISSN":["2667-0895"],"issn-type":[{"type":"print","value":"2667-0895"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}